Pruritus Therapeutics Market (By Disease Type: Atopic Dermatitis, Allergic Contact Dermatitis, Urticaria; By Product: Corticosteroids, Antihistamines) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2024-2033

The global pruritus therapeutics market was valued at USD 8.68 billion in 2023 and is predicted to hit around USD 12.89 billion by 2033 with a CAGR of 4.03% from 2024 to 2033. 

Key Pointers

• North America dominated the market and accounted for the largest revenue share of 41% in 2023. 
• Asia Pacific is expected to grow at the fastest CAGR of 5.24% over the forecast period.
• The atopic dermatitis segment held the largest revenue share of around 32% in 2023. 
• The urticaria segment is projected to grow at the fastest CAGR of more than 4.07% between 2024 to 2033. 
• The corticosteroids segment dominated the market with a revenue share of 26% in 2023. 
• The calcineurin inhibitors segment is anticipated to grow at a CAGR of 4.94% from 2024 to 2033.

Pruritus Therapeutics Market Overview

The pruritus therapeutics market encompasses a diverse array of treatments aimed at addressing the challenging symptom of pruritus, commonly known as itching. This market overview delves into the landscape of pruritus therapeutics, exploring the various factors influencing its growth and evolution.

Pruritus, characterized by an intense and often persistent itching sensation, can arise from a multitude of underlying conditions, including dermatological, systemic, and neurological disorders. As such, the demand for effective pruritus therapeutics remains high, driven by the need to alleviate patient discomfort and improve their quality of life.

Pruritus Therapeutics Market Growth Factors

The growth of the pruritus therapeutics market is driven by an increasing prevalence of pruritic conditions worldwide contributes to a growing patient population in need of effective treatment options. Additionally, the rise in geriatric population, who are more susceptible to pruritus due to age-related changes in skin and underlying health conditions, further drives market growth. Furthermore, expanding awareness among healthcare professionals and patients about the importance of pruritus management encourages early diagnosis and treatment initiation, thereby boosting market demand. Moreover, ongoing research and development efforts aimed at discovering novel therapeutics and understanding the underlying mechanisms of itch sensation offer promising avenues for market expansion. 

Report Scope of the Pruritus Therapeutics Market

Pruritus Therapeutics Market Trends:

• Advancements in Biologic Therapies: The development of biologic drugs targeting specific pathways involved in itch sensation represents a significant trend in pruritus therapeutics. These therapies offer targeted treatment options with potentially fewer side effects compared to traditional systemic medications.
• Focus on Patient-Centric Solutions: Pharmaceutical companies are increasingly prioritizing patient-centric approaches in the development of pruritus therapeutics. This includes the formulation of convenient dosage forms, such as topical creams or oral tablets, as well as patient support programs to enhance treatment adherence and satisfaction.
• Integration of Digital Health Technologies: The integration of digital health technologies, such as mobile applications and wearable devices, into pruritus management is emerging as a trend. These technologies enable remote monitoring of patient symptoms, facilitate communication between patients and healthcare providers, and offer personalized treatment recommendations.
• Expansion of Over-the-Counter (OTC) Products: There is a growing market for over-the-counter pruritus relief products, including topical creams, lotions, and antihistamine medications. Consumers are increasingly seeking self-care solutions for mild to moderate itching, driving the demand for OTC pruritus therapeutics.
• Personalized Medicine Approaches: Advances in genomics and biomarker research are paving the way for personalized medicine approaches in pruritus management. By identifying genetic predispositions and molecular markers associated with specific pruritic conditions, healthcare providers can tailor treatment strategies to individual patient needs, optimizing therapeutic efficacy.
• Rising Demand for Natural and Herbal Remedies: There is a growing consumer preference for natural and herbal remedies for pruritus relief, driven by concerns about the potential side effects of conventional medications. As a result, there is increasing research and development focus on botanical extracts and traditional herbal remedies with anti-itch properties.

Disease Type Insights

Based on disease type, the market is segmented into internal diseases, atopic dermatitis, allergic contact dermatitis, urticaria, and others. The atopic dermatitis segment held the largest revenue share of around 32% in 2023. Eczema or atopic dermatitis is one of the most common chronic skin diseases, often beginning in early childhood. Skin conditions may be associated with allergic rhinitis, asthma, and food allergies. Certain foods such as citrus fruits, eggs, tomatoes & milk can also cause eczema in young children. According to National Eczema Association, approximately 9.6 million U.S. children under the age of 18 have atopic dermatitis, and one-third have moderate to severe disease.

The urticaria segment is projected to grow at the fastest CAGR of more than 4.07% over the forecast period. Urticaria, or hives is a common, severely itchy skin disorder that causes red, itchy, raised bumps that are millimeters to centimeters in size. They can appear anywhere on the body and have a lifetime prevalence of approximately 20%. Most allergists prescribe antihistamines such as cetirizine, fexofenadine, and loratadine to reduce symptoms of urticaria. 

Product Insights

Based on product, the market is categorized into corticosteroids, local anesthetics, counterirritants, antihistamines, calcineurin inhibitors, immunosuppressants, and others. The corticosteroids segment dominated the market with a revenue share of 26% in 2023. Corticosteroids are anti-inflammatory drugs and are used to provide comfort by reducing inflammation. A few corticosteroids include cortisone, dexamethasone, prednisolone, and hydrocortisone. Additionally, corticosteroids lessen allergic responses, itching, swelling, and redness. They are applied to numerous types of pruritus. Due to their wide range of uses, corticosteroids are common pruritus treatments, which accounts for their market domination.

The calcineurin inhibitors segment is anticipated to grow at a CAGR of 4.94% during the forecast period due to its strong pipeline and its high response rate. Tacrolimus is a calcineurin inhibitor that stops the immune system from reacting severely by blocking calcineurin, one of the chemicals that contributes to eczema flares.

Regional Insights

North America dominated the market and accounted for the largest revenue share of 41% in 2023. The introduction of new products and the presence of favorable government initiatives are some key factors attributing to its large share. Furthermore, the growing prevalence of target diseases and the presence of pruritus-inducing climatic conditions in the region are expected to drive market growth during the forecast period. According to National Eczema Association, 31.6 million people were suffering from some form of eczema, and prevalence peaks during early childhood in the U.S. in 2019.

Asia Pacific is expected to grow at the fastest CAGR of 5.24% over the forecast period due to the presence of unmet healthcare infrastructure needs and the increasing prevalence of atopic dermatitis and urticaria. According to an article published in the Indian Journal of Community Medicine (IJCM), 20% of the Indian population was suffering from skin diseases in 2020. Infections and eczema accounted for two-thirds of skin conditions in the study population.

Pruritus Therapeutics Market Key Companies

• Abbvie, Inc.
• Actavis Plc
• Amgen, Inc.
• Astellas Pharma
• Bristol-Myers Squibb
• Cara Therapeutics
• GlaxoSmithKline, Plc.
• Myaln NV
• Novartis AG
• Pfizer Inc.
• Sanofi
• Teva Pharmaceuticals

Pruritus Therapeutics Market Segmentations:

By Disease Type 

• Atopic Dermatitis
• Allergic Contact Dermatitis
• Urticaria
• Others

By Product 

• Corticosteroids
• Antihistamines
• Local Anesthetics
• Counterirritants
• Immunosuppressant
• Calcineurin Inhibitors
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa